More MS news articles for June 2001

STOCKWATCH: Schering lower on fears Betaferon will be trumped by Serono, Biogen

Last update 14:40:06 GMT
June 22

FRANKFURT (AFX) - Shares in Schering AG were lower midafternoon amid expectations that its multiple sclerosis treatment Betaferon Rebif will be overshadowed by rival products from Serono SA and Biogen Inc, dealers said.

At 3.16 pm, Schering shares were down 1.45 eur or 2.26 pct at 62.85. The DAX 30 was at 5,922.19, down 4.19 points or 0.07 pct.

The three drugs are currently pitted against each other in a head-to-head clinical trial in the U.S.